ENIA11 + methotrexate

ENIA11 + methotrexate is a combination therapy under investigation for the treatment of rheumatoid arthritis. ENIA11 is administered at 25 mg subcutaneously twice weekly in combination with methotrexate. The combination aims to enhance efficacy compared to methotrexate monotherapy, which is the current standard of care in rheumatoid arthritis. The mechanism of action of ENIA11 is not specified in the available sources. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits enzymes involved in folate metabolism, leading to anti-inflammatory and antiproliferative effects. The combination is being evaluated in multicenter, double-blind, randomized, placebo-controlled Phase III studies in patients with rheumatoid arthritis[1][3][5].